CFM
LYEL icon

Catalyst Funds Management’s Lyell Immunopharma LYEL Stock Holding History

Catalyst Funds Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,365
Closed -$105K – 1414
2024
Q1 		$105K Buy
+2,365
New +$101K 0.03% 383

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Funds Management's LYEL Position: Q2 2024 in Review

Catalyst Funds Management sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 2,365 shares — an estimated $105K sold.

Catalyst Funds Management first reported a position in LYEL in Q1 2024 and held it in 1 quarter. The position peaked at $105K in Q1 2024. 120 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

  • Catalyst Funds Management reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 2,365 Lyell Immunopharma shares in Q2 2024, an estimated $105K.
  • Catalyst Funds Management first reported a position in Lyell Immunopharma in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Lyell Immunopharma position peaked at $105K in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.